Barrons.com1d agoneutral
AstraZeneca-Bristol Myers: The Floodgates for Biotech Mergers Are OpenEven if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
530last 24h
2512last 7d
483● bullish (7d)
257● bearish (7d)
197publishers
PA Media: Money1d agoneutral
Stocks mixed as AstraZeneca merger talk dents FTSE 100The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.
MT Newswires4d agoneutral
AbbVie Trims Full-Year Profit Outlook Due to Apogee AcquisitionAbbVie (ABBV) lowered its full-year earnings guidance on Friday to account for the expected dilution
The Wall Street Journal5d agobullish
AbbVie Lowers Outlook to Account for Acquisition as Profit JumpsAbbVie lowered its full-year adjusted earnings outlook to account for its acquisition of Apogee Therapeutics, as the company logged higher profit and revenue in the recent quarter.
GuruFocus.com14d agobullish
Biotech IPOs Surge 55% as AI Listings Lose MomentumStrong biotech returns, major pharma acquisitions and new IPO filings are reshaping the 2026 U.S. listing market.
Motley Fool16d agoneutral
How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?There's no need to panic.
Insider Monkey34d agobullish
H.C. Wainwright Keeps Buy Rating on Oruka (ORKA) After Apogee Acquisition NewsOruka Therapeutics, Inc. (NASDAQ:ORKA) is one of the Top 10 Hot Stocks with the Highest Upside Potential. On June 23, H.C. Wainwright reaffirmed its Buy rating on Oruka Therapeutics, Inc. (NASDAQ:ORKA) with a price target of $120 on the stock. This update comes after AbbVie announced that it is acquiring Apogee Therapeutics. AbbVie said that […]
Motley Fool35d agobullish
This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?AbbVie knows how to plan ahead.
Insider Monkey43d agoneutral
Wells Fargo Maintains Overweight on AbbVie (ABBV), Sees Value in Apogee AcquisitionWith a 5-Year Average Dividend Growth Rate of 6.33%, AbbVie Inc. (NYSE:ABBV) is included among the Top 11 Dividend Kings to Buy for Safe Dividend Growth. On June 22, Wells Fargo maintained an Overweight rating on AbbVie Inc. (NYSE:ABBV). It also set a $260 price target on the shares. The firm said AbbVie’s reported bid […]
Insider Monkey43d agoneutral
Apogee Therapeutics (APGE) Hits Fresh High on AbbVie $10.9B MergerApogee Therapeutics Inc. (NASDAQ:APGE) is one of the 10 Stocks Paying Off Big Time. Apogee Therapeutics soared to a fresh all-time high on Monday, as investors gobbled up shares following announcements that it is set to be acquired by pharmaceutical giant AbbVie Inc. at a 49 percent premium. In a joint statement on the same […]
Quartz44d agoneutral
AbbVie acquires Apogee Therapeutics for $10.9 billionThe all-cash deal gives AbbVie access to zumilokibart, an experimental drug that could rival Dupixent in treating atopic dermatitis